The emerging burden of triple-negative breast cancer in Australia: Universal care does not guarantee equitable access

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with early onset, limited targeted treatment options, and disproportionately high mortality. Although Australia operates a universal health-care system, inequities in TNBC outcomes persist. We synthesise contemporary clinical, epidemiological, and policy evidence to examine how structural, socioeconomic, and social determinants of health shape access to diagnosis, treatment initiation, treatment completion, and benefit from emerging TNBC therapies. Although public subsidy has reduced direct healthcare costs, particularly following the introduction of peri-operative immunotherapy, financial protection alone has not translated into equitable outcomes. Persistent barriers related to cultural safety, health literacy, geographic remoteness, housing insecurity, indirect costs, and fragmented service delivery continue to limit effective access for priority populations, including Aboriginal and Torres Strait Islander (ATSI) communities, and those experiencing socioeconomic disadvantage. These inequities are further compounded by variations in clinical pathways, workforce availability, and clinical trial participation. TNBC therefore illustrates the limitations of universal coverage models that priorities funding equity without addressing broader structural constraints on care. Achieving population-wide benefit will require policy responses that integrate medicine funding with system-level reforms targeting service accessibility, culturally safe care, and social support mechanisms across the cancer care continuum.